

PEPTIDE

Liraglutide

GLP-1 receptor agonist with ~13 hour half-life via albumin-binding palmitoyl chain; daily SC dosing for glycemic control and weight loss.

BIOGATE · AMBER POSTERIOR 26.6% MW 3751.2 31AA

SEQUENCE

HAEGTFTSDVSSYLEGQAAKEFIAWLVRGRG

Modifications: Glu-C16 palmitoyl sidechain @ K20

PDA-V1 chain of custody

Outer hash

965-
aad5c975aaeef985ab082995ab215925aa710935aa8a3945aaa3695

Merkle root

39-
e6191338e617803be61c393ae61aa63de61f5f3ce61dcc3fe622853ee620f2

Inputs

1907-
eadc1a07ec6f1b07ee021c07ef951507e4901607e6231707e7b6180

TEE attestation

3-
d60ffb13c60fe1e3b60fc8b3a60faf8416105fd4061046a3f6102d73e610144

Living Outcome Oracle

± 28.7

² = 79.1

P(success) = 26.6%

95% CI [14.6%, 38.6%]

Seven-rule export gate

7 / 7 rules satisfied · audience: researcher · Full attestation set, raw posteriors, all hashes

- Grade A or B citation present on the core claim
- BioGate verdict is GREEN or AMBER (RED/BLACK refused)
- Jurisdiction permits the audience-appropriate use
- RWE summary attached when claim depends on outcome data
- Prediction-outcome pairs disclosed when posterior cited
- No human-use claim beyond cited indications
- COA registry lookup available for any synthesis claim

Citations

GRADE A

2015 · N Engl J Med

A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE)

Pi-Sunyer X et al.

[PMID 26132939](#)